[HTML][HTML] Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors
Background Epidermal growth factor receptor (EGFR) signaling plays an important role in
non-small cell lung cancer (NSCLC) and therapeutics targeted against EGFR have been …
non-small cell lung cancer (NSCLC) and therapeutics targeted against EGFR have been …
Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer
K Suda, I Murakami, T Katayama, K Tomizawa… - Clinical cancer …, 2010 - AACR
Purpose: In epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
for lung cancer patients, acquired resistance develops almost inevitably and this limits the …
for lung cancer patients, acquired resistance develops almost inevitably and this limits the …
[HTML][HTML] Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells
K Tabara, R Kanda, K Sonoda, T Kubo, Y Murakami… - PLoS …, 2012 - journals.plos.org
Non-small-cell lung cancer harboring epidermal growth factor receptor (EGFR) mutations
attains a meaningful response to EGFR-tyrosine kinase inhibitors (TKIs). However, acquired …
attains a meaningful response to EGFR-tyrosine kinase inhibitors (TKIs). However, acquired …
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer
JA Engelman, PA Jänne - Clinical Cancer Research, 2008 - AACR
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are
effective therapies for non–small cell lung cancer patients whose tumors harbor somatic …
effective therapies for non–small cell lung cancer patients whose tumors harbor somatic …
Characterising acquired resistance to erlotinib in non-small cell lung cancer patients
N Karachaliou, J Codony-Servat… - Expert Review of …, 2019 - Taylor & Francis
Introduction: The therapy of patients with lung adenocarcinoma has significantly changed
after the discovery of epidermal growth factor receptor (EGFR) mutations. EGFR mutations …
after the discovery of epidermal growth factor receptor (EGFR) mutations. EGFR mutations …
Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies
Z Yu, TJ Boggon, S Kobayashi, C Jin, PC Ma, A Dowlati… - Cancer research, 2007 - AACR
Patients with epidermal growth factor receptor (EGFR)–mutant non–small cell lung cancer
derive significant clinical benefit from treatment with the EGFR tyrosine kinase inhibitors …
derive significant clinical benefit from treatment with the EGFR tyrosine kinase inhibitors …
[HTML][HTML] Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review
Lung cancer is the leading cause of cancer related deaths in Canada with non-small cell
lung cancer (NSCLC) being the predominant form of the disease. Tumor characterization …
lung cancer (NSCLC) being the predominant form of the disease. Tumor characterization …
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
D Ercan, K Zejnullahu, K Yonesaka, Y Xiao… - Oncogene, 2010 - nature.com
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib are
effective therapies against mutant non-small cell lung cancers (NSCLCs). Treatment is …
effective therapies against mutant non-small cell lung cancers (NSCLCs). Treatment is …
Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib
Y Xu, H Liu, J Chen, Q Zhou - Cancer biology & therapy, 2010 - Taylor & Francis
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib
and erlotinib, are the first targeted therapy drugs approved for the treatment of advanced non …
and erlotinib, are the first targeted therapy drugs approved for the treatment of advanced non …
Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma
K Politi, PD Fan, R Shen… - Disease models & …, 2010 - journals.biologists.com
Seventy-five percent of lung adenocarcinomas with epidermal growth factor receptor (EGFR)
mutations respond to treatment with the tyrosine kinase inhibitors (TKIs) gefitinib and …
mutations respond to treatment with the tyrosine kinase inhibitors (TKIs) gefitinib and …